Question webs

A question web lays out every question asked about one company's FDA and SEC record, joining those whose answers quote the same passage. How to read it.

A question web is one company's regulatory history after an FDA letter, broken into the questions it raises. Open one from the deep research home page: click anywhere on a company's card, or Open the web →.

Parts of the page#

Replimune's question web: the title RP1 after the FDA's letters: the record, reconstructed, a lead with the number of questions and source documents, a Web and Timeline switch, a legend, and question cards joined by lines. — Figure 1. Replimune's question web (/research/deep-research/companies/replimune/).

1Company line. The company, its ticker and the product the letters concern.
2Lead. The record in one sentence: the FDA actions it covers, how many questions were asked and how many source documents answer them.
3Web / Timeline. Switches between the web (questions and their connections) and the timeline (questions by period and theme).
4Legend. Quotes an FDA letter (blue), Quotes a company filing (orange), and what a line means.
5A question. Its period (for example JUL 2025, or a range such as 2021 – 2026 for a question that spans the record) and the question itself. Click it to open its question page.
6Evidence line. Coloured dots for the kinds of source its answer quotes, the number of documents, and how many other questions it is connected to.
7Connections. A line joins two questions whose answers quote the same passage.

What a connection means#

Two questions are joined only when both of their answers cite the same passage of the same document, or the same “not in” search. A connection is never a judgement that two topics are related. It is a fact about the evidence: these two answers lean on the same words.

That makes the web useful in two ways:

A heavily connected question is a load-bearing one. On Replimune's web, What happened to the confirmatory trial Replimune said would not be viable? has five connections. The Phase 3 control arm links it to the first letter and the Type A meeting minutes; Replimune's words “will not be viable” link it to the 8-K on the first letter and to the job cuts after the second; and the need for a confirmatory trial links it to what remains unresolved after approval.
A passage that answers questions from different periods shows continuity. When a 2021 meeting note answers both a 2021 question and a 2026 one, the concern has a history, and the web shows it.

Trace a question#

Point at a question to trace it. The question and the questions it shares evidence with stay dark; everything else fades. A panel, Shares evidence with, lists each connected question with the shared passage in a few words.

Replimune's web with the question What did the FDA's second letter object to? highlighted. Four connected questions stay dark, the rest fade, and a panel titled Shares evidence with lists them, each with a short label such as Phase 3 data insufficient and Unanimously determined. — Figure 2. Tracing *What did the FDA's second letter object to?*: four questions share its evidence.

Each label in the panel names what is shared: Phase 3 data “insufficient”, “Unanimously determined”. Click a question in the panel to open it.

The timeline#

Click Timeline to see the same questions arranged by period (rows) and theme (columns).

Replimune's timeline: rows for Before the application, First Complete Response Letter and Type A meeting and resubmission, each with dated events on the left, and question cards in columns headed The FDA's position, Replimune's account, The clinical evidence and The trial and the company. — Figure 3. The timeline view. FDA actions are blue diamonds; each row lists the dated events in that period.

Rows are periods, from before the application to after the latest decision. A row headed by an FDA action (a ◆ Complete Response Letter, an approval) is marked in blue.
The left column lists dated events: meetings, letters, 8-Ks, resubmissions, lawsuits. A blue dot is an FDA action or letter; an orange dot is a company filing.
Columns are themes. On Replimune's web: The FDA's position, Replimune's account, The clinical evidence and The trial and the company. Reading across a row compares what each side said in the same period.
The last row, Across the record, holds questions that span the whole history, such as Was the FDA's advice to Replimune consistent?

Hover a question here too, to see which others share its evidence.

Companies#

Question webs are published for companies that received an FDA Complete Response Letter and reported it to the SEC:

Company	Product	Questions	Source documents
Aldeyra Therapeutics	reproxalap	9	16
CorMedix	DefenCath	9	20
Outlook Therapeutics	ONS-5010	9	21
Replimune	RP1	16	11
Verrica Pharmaceuticals	VP-102	9	16

Cases#

A case is a question web built around one FDA decision rather than one company. It reads the FDA's own documents alongside what other companies have filed about that decision, and stops at the next decision that is still open. Cases make no predictions. Open them from the Cases entrance, or from the case links at the top of the deep research home page.

Case	What it follows
INO-3107 and the PAPZIMEOS precedent	What the FDA accepted when it approved Precigen's PAPZIMEOS for recurrent respiratory papillomatosis, and what INOVIO has disclosed about its own application for INO-3107, before the FDA's October 30, 2026 goal date.
Jaypirca: what changed in the evidence	Four FDA approvals of Jaypirca (pirtobrutinib) from 2023 to 2026, and how the evidence behind each changed: two accelerated approvals, a traditional approval and an approval in previously untreated patients.

A case web works like a company web: the same Web and Timeline views, the same connections, the same question pages. The legend reads Quotes an FDA document rather than an FDA letter, because a case also quotes approval letters and review summaries.

Every question at once#

The Investigations entrance lists every question in the company webs on one page, grouped by company: a quick way to scan the research for a topic without opening each web.

Why a web, not an article#

A regulatory history is not a straight line. The same concern can surface in a 2021 meeting, disappear from the first letter, and open the second. A single article has to pick one order to tell it in; a web keeps every question separately answerable and shows where they overlap. You can enter at the question you care about and follow the evidence outwards, instead of reading from the beginning. See What deep research means.